Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Industry association · Netherlands
Declared costs: €50K+ a year · in the register since 2023
NGO · Germany
Declared costs: not declared · in the register since 2008
Medicinal products for human use · A European Health Data Space · Revision of the EU legislation on medicines for children and rare diseases · Supplementary protection certificate for plant protection products. Recast
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Vereniging Innovatieve Geneesmiddelen · filed 26 Apr 2021 · source
The Vereniging Innovatieve Geneesmiddelen (VIG) considers the evaluation of the pharmaceutical legislation an opportunity to draw lessons from the COVID-19 pandemic and prepare for the future. To remain attractive for innovation and R&D while effectively responding to future challenges and threats.
Deutsche Sozialversicherung Europavertretung · filed 27 Apr 2021 · source
Health systems in the EU face the challenge of ensuring a high quality of affordable supply of medicines in the face of high prices. The German Social Insurance Agency therefore welcomes the EU’s intention to revise European pharmaceutical legislation.
Filed in German · English published by the European Commission
Deutsche Sozialversicherung Europavertretung · filed 2 Nov 2023 · source
The German Social Insurance Board (DSV) welcomes the Commission’s objectives of the reform proposals. They provide an opportunity to ensure equal access to medicines for patients in all Member States and to strengthen the security of supply of medicines as well as the adequacy of existing incentive schemes for drug development.
Filed in German · English published by the European Commission
Vereniging Innovatieve Geneesmiddelen · filed 7 Nov 2023 · source
On behalf of the Association Innovative Medicines (VIG), the Dutch industry association of 44 innovative medicines manufacturers, our response to the proposed revision of the EU pharmaceutical legislation. The members of the VIG are active in the biopharmaceutical ecosystem of the Netherlands, which extends from academic institutions and hospitals to medicine developers and service companies.
Filed in Dutch · English published by the European Commission
Vereniging Innovatieve Geneesmiddelen · filed 7 Nov 2023 · source
On behalf of the Association Innovative Medicines (VIG), the Dutch industry association of 44 innovative medicines manufacturers, our response to the proposed revision of the EU pharmaceutical legislation. The members of the VIG are active in the biopharmaceutical ecosystem of the Netherlands, which extends from academic institutions and hospitals to medicine developers and service companies.
Filed in Dutch · English published by the European Commission
Deutsche Sozialversicherung Europavertretung · filed 2 Feb 2021 · source
The German social security umbrella organisations welcome the European Commission’s intention to shape a European health data space, in particular by: — a more binding cooperation between Member States to improve the availability and interoperability of health data with added value for patients; and — the creation of institutionalised data Governance Structure, research and development of innovation and the…
Filed in German · English published by the European Commission
Vereniging Innovatieve Geneesmiddelen · filed 4 Feb 2021 · source
The Vereniging Innovatieve Geneesmiddelen (VIG) is positive towards the proposal of the European Commission to establish a European Health Data Space (EHDS). This proposal enables the EU to better grasp the potential of health data for research and innovation on new preventive strategies, as well as on diagnosis and treatment of diseases to improve health outcomes.
Deutsche Sozialversicherung Europavertretung · filed 4 Jan 2021 · source
The German social security umbrella organisations in Germany welcome the plan to revise the existing incentive schemes for orphan medicinal products and paediatric medicinal products and agrees with the European Commission that the aim of this revision must be to: (1) focus support on areas where the regulations have not shown the desired success; (2) end support for areas where it is not necessary; (3) link funding…
Filed in German · English published by the European Commission
Vereniging Innovatieve Geneesmiddelen · filed 6 Jan 2021 · source
Pharmaceutical companies are committed to develop solutions for unmet needs and to ensure available treatments reach all patients in Europe. Patients with rare diseases and children have benefited greatly from the progress which has been realised with the OMP Regulations.
Vereniging Innovatieve Geneesmiddelen · filed 4 Apr 2022 · source
The development and marketing of new medicines requires time and investment in research, the outcome of which is uncertain: many developments do not lead to a useful medicine. There is no doubt that a well-functioning IP system is indispensable for a good innovation and investment environment.
Filed in Dutch · English published by the European Commission
Deutsche Sozialversicherung Europavertretung · filed 4 Apr 2022 · source
The European Commission is examining measures to optimise the existing system of Supplementary Protection Certificates (SPCs) in order to make it more transparent and efficient. SPCs are an intellectual property protection instrument that has the effect of extending the term of protection of a pharmaceutical patent by up to five years.
Filed in German · English published by the European Commission
Deutsche Sozialversicherung Europavertretung · filed 19 Sept 2023 · source
On April 27, 2023, the European Commission submitted proposals for the reform of intellectual property rights for medicinal products. Among other things, a unitary European supplementary protection certificate is to be established to complement the unitary European patent already introduced by Regulations (EU) No. 1257/2012 and (EU) No. 1260/2012 and due to start in 2023.
Deutsche Sozialversicherung Europavertretung · filed 19 Sept 2023 · source
On April 27, 2023, the European Commission submitted proposals for the reform of intellectual property rights for medicinal products. Among other things, a unitary European supplementary protection certificate is to be established to complement the unitary European patent already introduced by Regulations (EU) No. 1257/2012 and (EU) No. 1260/2012 and due to start in 2023.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.